secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001493152-22-033823
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals sells rights to generic Sabril (vigabatrin) ANDA to Pyros
-------------------------------------------------------------------------------

- Sale of rights to approved ANDA for generic Sabril (Vigabatrin Powder for Oral Solution, 500 mg) to Pyros Pharmaceuticals.
- Elite executed a three-year manufacturing and supply agreement with Pyros for the product.
- Elite will be compensated at an agreed-upon price for manufacturing and packaging.
- Agreement executed November 21, 2022; sale has been consummated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/0001493152-22-033823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-033823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer